Taylor Adam M, Vercruysse Koen P
Faculty of Health and Medicine, Lancaster Medical School, Lancaster University, Bailrigg, Lancaster, LA1 4YW, UK.
Department of Chemistry, Tennessee State University, Nashville, TN, 37209, USA.
JIMD Rep. 2017;35:79-85. doi: 10.1007/8904_2016_27. Epub 2016 Dec 10.
Alkaptonuria is an iconic disease used by Archibald Garrod to demonstrate the theory of "inborn errors of metabolism". AKU knowledge has advanced in recent years: development of an in vitro model, discovery of murine models and advances in understanding bone and cartilage phenotypes and arthropathy in AKU. These discoveries have aided in a new clinical trial into nitisinone. However, there are still knowledge gaps surrounding the pigment in AKU and the pigmentation process. We demonstrate an advance in the understanding in the kinetics and chemistry of the polymerisation of homogentisic acid (HGA) into its pigment using size-exclusion chromatography and IR spectroscopy. We compared the properties of HGA-based pigments that were freshly prepared to those stored in solution for 2 years. Our results demonstrate the importance of pH in the polymerisation process and that colour change seen in solution (analogous to AKU patient urine) is not initially due to presence of ochronotic pigment but the quinone intermediary. In addition, we observed that pigment formation from HGA can occur in the presence of tyrosine, without the inclusion of this tyrosine into the pigment. These observations have positive implications for patients with alkaptonuria; an increased understanding of the pigment polymer chemistry, the presence of an intermediary and their kinetics present more therapeutic opportunities for treating the condition, including preventing the pigment from forming, binding or reversing established pigmentation. AKU patients treated with nitisinone show elevated tyrosine levels causing side effects such as corneal opacities; our data demonstrates that elevated tyrosine levels should not contribute or add to the ochronotic pigment burden in these patients.
黑尿症是阿奇博尔德·加罗德用来论证“先天性代谢缺陷”理论的一种标志性疾病。近年来,关于黑尿症的知识有了进展:建立了体外模型,发现了小鼠模型,并且在理解黑尿症的骨骼和软骨表型以及关节病方面取得了进展。这些发现有助于开展一项关于nitisinone的新临床试验。然而,围绕黑尿症中的色素及其色素沉着过程仍存在知识空白。我们利用尺寸排阻色谱法和红外光谱法,在对尿黑酸(HGA)聚合成其色素的动力学和化学过程的理解上取得了进展。我们比较了新制备的基于HGA的色素与在溶液中储存两年的色素的性质。我们的结果证明了pH在聚合过程中的重要性,并且溶液中看到的颜色变化(类似于黑尿症患者的尿液)最初并非由于褐黄病色素的存在,而是由于醌中间体。此外,我们观察到在酪氨酸存在的情况下,HGA可以形成色素,而酪氨酸并未掺入色素中。这些观察结果对黑尿症患者具有积极意义;对色素聚合物化学、中间体的存在及其动力学的更多了解为治疗该疾病提供了更多治疗机会,包括防止色素形成、结合或逆转已有的色素沉着。用nitisinone治疗的黑尿症患者酪氨酸水平升高会导致诸如角膜混浊等副作用;我们的数据表明,酪氨酸水平升高不应增加这些患者的褐黄病色素负担。